GU Cancers 2025 | Promising biomarkers of response to immunotherapies in kidney cancer
Wenxin Xu
• 13 Feb 2025
Wenxin Xu, MD, Dana-Farber Cancer Institute, Boston, MA, comments on emerging biomarkers in kidney cancer, which remain an unmet need. PD-L1 expression has shown mixed results in previous trials, and transcriptomic signatures are being explored as potential predictors of response to immunotherapy versus anti-angiogenic therapies. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
